预约演示

更新于：2025-05-07

KrasG12D siRNA-loaded mesenchymal stromal cells-derived exosomes (Codiak BioSciences)

更新于：2025-05-07

概要

概要

基本信息

药物类型

外泌体药物、siRNA

别名

MSC-derived Exosomes with KrasG12D siRNA(Codiak BioSciences)、Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA(Codiak BioSciences)、iExosomes

靶点

KRAS G12D

作用方式

抑制剂

作用机制

KRAS G12D抑制剂(KRAS G12D突变抑制剂)

治疗领域

肿瘤消化系统疾病内分泌与代谢疾病

在研适应症

转移性胰腺癌转移性胰腺导管腺癌转移性胰腺腺癌

非在研适应症-

原研机构

MD Anderson Cancer Center Orlando

在研机构

The University of Texas MD Anderson Cancer Center

非在研机构

Codiak BioSciences, Inc.

权益机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

使用我们的RNA技术数据为新药研发加速。

或

查看完整样例数据

关联

项与 KrasG12D siRNA-loaded mesenchymal stromal cells-derived exosomes (Codiak BioSciences) 相关的临床试验

NCT03608631

/ Active, not recruiting临床1期IIT

Phase I Study of Mesenchymal Stromal Cells-Derived Exosomes With KrasG12D siRNA for Metastatic Pancreas Cancer Patients Harboring KrasG12D Mutation

This phase I trial studies the best dose and side effects of mesenchymal stromal cells-derived exosomes with KrasG12D siRNA (iExosomes) in treating participants with pancreatic cancer with KrasG12D mutation that has spread to other places in the body. iExosomes may work better at treating pancreatic cancer.

开始日期2021-01-27

申办/合作机构

The University of Texas MD Anderson Cancer Center

100 项与 KrasG12D siRNA-loaded mesenchymal stromal cells-derived exosomes (Codiak BioSciences) 相关的临床结果

登录后查看更多信息

100 项与 KrasG12D siRNA-loaded mesenchymal stromal cells-derived exosomes (Codiak BioSciences) 相关的转化医学

登录后查看更多信息

100 项与 KrasG12D siRNA-loaded mesenchymal stromal cells-derived exosomes (Codiak BioSciences) 相关的专利（医药）

登录后查看更多信息

项与 KrasG12D siRNA-loaded mesenchymal stromal cells-derived exosomes (Codiak BioSciences) 相关的文献（医药）

2017-06-01·Nature

Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer

Article

作者: Lee, J Jack ; LeBleu, Valerie S ; Yang, Sujuan ; Kalluri, Raghu ; Ruivo, Carolina F ; Sugimoto, Hikaru ; Kamerkar, Sushrut ; Melo, Sonia A

The mutant form of the GTPase KRAS is a key driver of pancreatic cancer but remains a challenging therapeutic target. Exosomes are extracellular vesicles generated by all cells, and are naturally present in the blood. Here we show that enhanced retention of exosomes, compared to liposomes, in the circulation of mice is likely due to CD47-mediated protection of exosomes from phagocytosis by monocytes and macrophages. Exosomes derived from normal fibroblast-like mesenchymal cells were engineered to carry short interfering RNA or short hairpin RNA specific to oncogenic Kras^G12D, a common mutation in pancreatic cancer. Compared to liposomes, the engineered exosomes (known as iExosomes) target oncogenic KRAS with an enhanced efficacy that is dependent on CD47, and is facilitated by macropinocytosis. Treatment with iExosomes suppressed cancer in multiple mouse models of pancreatic cancer and significantly increased overall survival. Our results demonstrate an approach for direct and specific targeting of oncogenic KRAS in tumours using iExosomes.

100 项与 KrasG12D siRNA-loaded mesenchymal stromal cells-derived exosomes (Codiak BioSciences) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
转移性胰腺导管腺癌	申请上市	美国	Codiak BioSciences, Inc.	2021-01-27
转移性胰腺癌	临床1期	美国	The University of Texas MD Anderson Cancer Center	2021-01-27
转移性胰腺导管腺癌	临床1期	美国	The University of Texas MD Anderson Cancer Center	2021-01-27
转移性胰腺腺癌	临床1期	美国	The University of Texas MD Anderson Cancer Center	2021-01-27